Bailard’s VYNE Therapeutics VYNE Stock Holding History

Bailard’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,743	Closed	-$91K	–	803
2022 Q1	$91K	Buy	+7,743	New	+$92K	﹤0.01%	698

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Bailard's VYNE Position: Q2 2022 in Review

Bailard sold out of VYNE Therapeutics (VYNE) in Q2 2022, closing a stake of 7,743 shares — an estimated $91K sold.

Bailard first reported a position in VYNE in Q1 2022 and held it in 1 quarter. The position peaked at $91K in Q1 2022. 41 funds tracked by Wall St. Rank hold VYNE as of Q2 2022.

Bailard reported no remaining VYNE Therapeutics position as of Q2 2022 after selling out during the quarter.
Bailard sold 7,743 VYNE Therapeutics shares in Q2 2022, an estimated $91K.
Bailard first reported a position in VYNE Therapeutics in Q1 2022 and held it in 1 quarter.
Bailard's VYNE Therapeutics position peaked at $91K in Q1 2022.
41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.